Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07653-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Bo Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical Scho…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Death, Sudden, Cardiac, Adverse Drug Reaction Reporting Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: NSFC, Natural Science Foundation of Hunan Province, Hunan Provincial Health High-Level Talent Scientific Research Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- The First Affiliated Hospital, Hengyang Clinical Pharmacology Research Center, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- The First Affiliated Hospital, Hengyang Key Laboratory of Clinical Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- The First Affiliated Hospital, Pharmacy Department, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
- The Affiliated Nanhua Hospital, Department of Docimasiology, Hengyang Medical School, University of South China, Hengyang, 421002, Hunan, China.
ORCID-Profile: Bo Xu, Tianqiao Zhang, Jiecan Zhou
Förderung
- NSFC
- Natural Science Foundation of Hunan Province
- Hunan Provincial Health High-Level Talent Scientific Research Project
- Hunan Province Clinical Medical Technology Innovation Guidance Project
- Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases
- The science and technology innovation Program of Hunan Province
Zitieren
APA
Xu, B., Zhang, T., Kang, B., Yang, X., Li, S., Chen, J., He, Z., & Zhou, J. (2025). Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07653-2
Vancouver
Xu B, Zhang T, Kang B, Yang X, Li S, Chen J, et al. Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07653-2
BibTeX
@article{Xu2025,
author = {Xu, Bo and Zhang, Tianqiao and Kang, Bo and Yang, Xiongwen and Li, Shaoqian and Chen, Jixiang and He, Zunbo and Zhou, Jiecan},
title = {Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07653-2}
}
EUVIMED